Clinical Trials in Los Angeles

Showing 2501-2520 of 8,046 trials

Advancing Postmenopausal Preventive Therapy

NCT04103476

Advancing Postmenopausal Preventive Therapy (APPT) is a randomized, double-blinded, placebo-controlled trial designed to determine the effects of tissue selective estrogen complex (TSEC) therapy on the progression of subclinical atherosclerosis and cognitive decline in 360 healthy postmenopausal women.

AtherosclerosisCognitive Decline

University of Southern California385 participantsStarted Apr 2021

Los Angeles, California, United States

TERMINATEDPhase 2< 1 mile

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

NCT04375527

This phase II trial studies how well binimetinib and nivolumab work in treating patients with BRAF V600 wildtype melanoma that has spread to nearby tissues or lymph nodes and cannot be removed by surgery (locally advanced unresectable) or has spread to other places in the body (metastatic). Binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving binimetinib and nivolumab together may work better in treating patients with melanoma compared to nivolumab alone.

Clinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Locally Advanced Cutaneous Melanoma+8 more

Jonsson Comprehensive Cancer Center3 participantsStarted Dec 2020

Los Angeles, California, United States

Active Not RecruitingPhase 2< 1 mile

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

NCT06119217

This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in subjects with metastatic PDAC who did not have prior treatment for metastatic disease and are eligible to receive gemcitabine and nab-paclitaxel chemotherapy as SOC.

Pancreatic Cancer

Trishula Therapeutics, Inc.194 participantsStarted Mar 2024

Tucson, Arizona, United States • Hot Springs, Arkansas, United States • Bakersfield, California, United States +61 more locations

Advancing Postmenopausal Preventive Therapy

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Find Trials by Condition in Los Angeles

Human Laboratory Study of ASP8062 for Alcohol Use Disorder

Randomized Study of Silq Urinary Catheter

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)

Effect of Korean Red Ginseng Extract on Blood Flow in Healthy Adults

Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy

Ocular Safety and Usability Study for FYB203 PFS

A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)

Hyrax Vs. Invisalign Palatal Expander Clinical Study

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

MIRACLE of LIFE Study

Study of the Resvent RXiBreeze™ PAP System to Treat Obstructive Sleep Apnea

Evaluation of Clear Aligner Trays to Straighten Teeth

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)